Bladder cancer: current challenges and future directions

J Dobruch, M Oszczudłowski - Medicina, 2021‏ - mdpi.com
Bladder cancer (BCa) is the most common malignancy of the urinary tract and one of the
most prevalent cancers worldwide. While the clinical approach to BCa has remained largely …

Treatment of muscle‐invasive and advanced bladder cancer in 2020

VG Patel, WK Oh, MD Galsky - CA: a cancer journal for …, 2020‏ - Wiley Online Library
Bladder cancer accounts for nearly 170,000 deaths worldwide annually. For over 4 decades,
the systemic management of muscle‐invasive and advanced bladder cancer has primarily …

Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial

MD Galsky, S Daneshmand, S Izadmehr… - Nature medicine, 2023‏ - nature.com
Cystectomy is a standard treatment for muscle-invasive bladder cancer (MIBC), but it is life-
altering. We initiated a phase 2 study in which patients with MIBC received four cycles of …

Pembrolizumab as neoadjuvant therapy before radical cystectomy in patients with muscle-invasive urothelial bladder carcinoma (PURE-01): an open-label, single …

A Necchi, A Anichini, D Raggi, A Briganti… - Journal of Clinical …, 2018‏ - ascopubs.org
Purpose To determine the activity of pembrolizumab as neoadjuvant immunotherapy before
radical cystectomy (RC) for muscle-invasive bladder carcinoma (MIBC) for which standard …

Treatment of non-metastatic muscle-invasive bladder cancer: AUA/ASCO/ASTRO/SUO guideline

SS Chang, BH Bochner, R Chou, R Dreicer… - The Journal of …, 2017‏ - auajournals.org
Purpose: This multidisciplinary, evidence-based guideline for clinically non-metastatic
muscle-invasive bladder cancer focuses on the evaluation, treatment and surveillance of …

Impact of molecular subtypes in muscle-invasive bladder cancer on predicting response and survival after neoadjuvant chemotherapy

R Seiler, HAD Ashab, N Erho, BWG van Rhijn… - European urology, 2017‏ - Elsevier
Background An early report on the molecular subty** of muscle-invasive bladder cancer
(MIBC) by gene expression suggested that response to neoadjuvant chemotherapy (NAC) …

Alterations in DNA damage response and repair genes as potential marker of clinical benefit from PD-1/PD-L1 blockade in advanced urothelial cancers

MY Teo, K Seier, I Ostrovnaya, AM Regazzi… - Journal of Clinical …, 2018‏ - ascopubs.org
Purpose Alterations in DNA damage response and repair (DDR) genes are associated with
increased mutation load and improved clinical outcomes in platinum-treated metastatic …

Safety and efficacy of durvalumab (MEDI4736), an anti–programmed cell death ligand-1 immune checkpoint inhibitor, in patients with advanced urothelial bladder …

C Massard, MS Gordon, S Sharma, S Rafii… - Journal of Clinical …, 2016‏ - ascopubs.org
Purpose To investigate the safety and efficacy of durvalumab, a human monoclonal antibody
that binds programmed cell death ligand-1 (PD-L1), and the role of PD-L1 expression on …

Somatic ERCC2 mutations are associated with a distinct genomic signature in urothelial tumors

J Kim, KW Mouw, P Polak, LZ Braunstein… - Nature …, 2016‏ - nature.com
Alterations in DNA repair pathways are common in tumors and can result in characteristic
mutational signatures; however, a specific mutational signature associated with somatic …

Molecular correlates of cisplatin-based chemotherapy response in muscle invasive bladder cancer by integrated multi-omics analysis

A Taber, E Christensen, P Lamy, I Nordentoft… - Nature …, 2020‏ - nature.com
Overtreatment with cisplatin-based chemotherapy is a major issue in the management of
muscle-invasive bladder cancer (MIBC), and currently none of the reported biomarkers for …